The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup conducted a workshop on Immune and Cellular Therapy in Multiple Myeloma on January 7, 2022. This workshop included presentations by basic, translational, and clinical researchers with expertise in plasma cell dyscrasias. Four main topics were discussed: platforms for myeloma disease evaluation, insights into pathophysiology, therapeutic target and resistance mechanisms, and cellular therapy for multiple myeloma. Here we provide a comprehensive summary of these workshop presentations.
Bibliographical noteFinancial disclosure: Support for the Blood and Marrow Transplant Clinical Trials Network was provided by Grants U10HL069294 and U24HL138660 from the National Heart, Lung, and Blood Institute and the National Cancer Institute (NCI). Support for the F.A. laboratory was provided by NCI Grant R01 CA252937. Support for the M.S. laboratory was provided by NCI Grant R01 CA248493. The content is solely the responsibility of the authors and does not reflect the views or the official policy or position of the National Institutes of Health.
© 2022 The American Society for Transplantation and Cellular Therapy